{"DataElement":{"publicId":"3109654","version":"1","preferredName":"Agent Patient Self-Report Hypersensitivity Type","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. Subjective reports made by a patient. A local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized._Something distinguishable as an identifiable class based on common qualities.","longName":"3109634v1.0:3109651v1.0","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"3109634","version":"1","preferredName":"Agent Patient Self-Report Hypersensitivity","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. Subjective reports made by a patient. A local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized.","longName":"2223333v1.0:3109632v1.0","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3109632","version":"1","preferredName":"Patient Self-Report Hypersensitivity","preferredDefinition":"Subjective reports made by the patient:A local or general reaction of an organism following contact with a specific allergen to which it has been previously exposed and to which it has become sensitized.","longName":"C21089:C3114","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient Self-Report","conceptCode":"C21089","definition":"Subjective reports made by a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Hypersensitivity","conceptCode":"C3114","definition":"An immune response that occurs following exposure to an innocuous antigen, but that does not require the presence of preformed antibodies to the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"890261CC-370E-8734-E040-BB89AD435793","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"BIRNBAUA","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"890261CC-371F-8734-E040-BB89AD435793","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"BIRNBAUA","dateCreated":"2010-06-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3109651","version":"1","preferredName":"Type Hypersensitivity","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities._An exaggerated response by the immune system to a drug or other substance.","longName":"0","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CE3A-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Sulfa","valueDescription":"Sulfa","ValueMeaning":{"publicId":"3109742","version":"1","preferredName":"Sulfa","longName":"3109742","preferredDefinition":"Sulfa","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8903BFCE-CE44-331C-E040-BB89AD431B7C","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CE5D-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Penicillin","valueDescription":"Penicillin Antibiotic","ValueMeaning":{"publicId":"2624960","version":"1","preferredName":"Penicillin Antibiotic","longName":"2624960","preferredDefinition":"An antibiotic drug used to treat infection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillin Antibiotic","conceptCode":"C1500","definition":"Any beta-lactam antibiotic derived from Penicillium fungi with bactericidal activity. Penicillin antibiotics bind to and inactivate penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing cell lysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2D5FB55C-F40C-122E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-05","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-04-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CE67-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Local Anesthetic","valueDescription":"Anesthetic Agent","ValueMeaning":{"publicId":"2746208","version":"1","preferredName":"Anesthetic Agent","longName":"2746208","preferredDefinition":"(an-es-THET-iks) Substances that cause loss of feeling or awareness. Local anesthetics cause loss of feeling in a part of the body. General anesthetics put the person to sleep.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anesthetic Agent","conceptCode":"C245","definition":"A pharmacological agent that acts in a reversible fashion and can be applied either locally or systemically to cause a partial or total loss of sensation and pain or to induce unconsciousness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C175B6C-FBAF-2303-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CE7B-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Latex","valueDescription":"Latex","ValueMeaning":{"publicId":"3109743","version":"1","preferredName":"Latex","longName":"3109743","preferredDefinition":"Latex","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8903BFCE-CE85-331C-E040-BB89AD431B7C","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CE9E-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Iodine","valueDescription":"Iodine","ValueMeaning":{"publicId":"2578182","version":"1","preferredName":"Iodine","longName":"2578182","preferredDefinition":"An element that is necessary for the body to make thyroid hormone.  It is found in shellfish and iodized salt.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iodine","conceptCode":"C594","definition":"An element with atomic symbol I, atomic number 53, and atomic weight of 126.90.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE73-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"DWARZEL","dateModified":"2006-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CEA8-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Codeine","valueDescription":"Codeine Phosphate","ValueMeaning":{"publicId":"2576059","version":"1","preferredName":"Codeine Phosphate","longName":"2576059","preferredDefinition":"An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Codeine","conceptCode":"C383","definition":"A naturally occurring phenanthrene alkaloid and opioid agonist with analgesic, antidiarrheal and antitussive activities. Codeine mimics the actions of endogenous opioids by binding to the opioid receptors at many sites within the central nervous system (CNS). Stimulation of mu-subtype opioid receptors results in a decrease in the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline; in addition, the codeine metabolite morphine induces opening of G-protein-coupled inwardly rectifying potassium (GIRK) channels and blocks the opening of N-type voltage-gated calcium channels, resulting in hyperpolarization and reduced neuronal excitability. Stimulation of gut mu-subtype opioid receptors results in a reduction in intestinal motility and delayed intestinal transit times. Antitussive activity is mediated through codeine's action on the cough center in the medulla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F628-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CEBC-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Barbiturates","valueDescription":"Barbiturate","ValueMeaning":{"publicId":"3109652","version":"1","preferredName":"Barbiturate","longName":"3109652","preferredDefinition":"A class of drugs characterized as central nervous system (CNS) depressants. Barbiturate compounds bind to the gamma amino butyric acid (GABA)-A receptor, thereby increasing the influx of chloride ions into the neuron and subsequently causing hyperpolarization, which produces a decrease in neuronal transmission. Other barbiturate effects in the CNS may include modulation of sodium and calcium channels as well as inhibition of glutamate-mediated excitation. Although the effects of barbiturates are seen throughout the CNS, the predominant effect occurs in the midbrain region, the part of the brain associated with arousal. CNS depressive effects associated with this drug class include mild sedation, hypnosis, anesthesia, and coma as well as a decrease in seizure activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barbiturate","conceptCode":"C67084","definition":"A class of drugs characterized as central nervous system (CNS) depressants. Barbiturate compounds bind to the gamma amino butyric acid (GABA)-A receptor, thereby increasing the influx of chloride ions into the neuron and subsequently causing hyperpolarization, which produces a decrease in neuronal transmission. Other barbiturate effects in the CNS may include modulation of sodium and calcium channels as well as inhibition of glutamate-mediated excitation. Although the effects of barbiturates are seen throughout the CNS, the predominant effect occurs in the midbrain region, the part of the brain associated with arousal. CNS depressive effects associated with this drug class include mild sedation, hypnosis, anesthesia, and coma as well as a decrease in seizure activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"890261CC-388A-8734-E040-BB89AD435793","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"BIRNBAUA","dateCreated":"2010-06-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CED0-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Aspirin","valueDescription":"Acetylsalicylic Acid","ValueMeaning":{"publicId":"2922827","version":"1","preferredName":"Acetylsalicylic Acid","longName":"2922827","preferredDefinition":"An orally administered non-steroidal antiinflammatory agent that inhibits cyclooxygenase synthesis of prostaglandin, preventing the formation of platelet aggregation and inflammation. It has analgesic and antipyretic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspirin","conceptCode":"C287","definition":"An orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F657-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8903BFCE-CEDA-331C-E040-BB89AD431B7C","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","deletedIndicator":"No"},{"value":"Contrast dye","valueDescription":"Contrast Agent","ValueMeaning":{"publicId":"3350342","version":"1","preferredName":"Contrast Agent","longName":"3350342","preferredDefinition":"Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Contrast Agent","conceptCode":"C390","definition":"Substances administered during imaging procedures that allows delineation of internal structures. Contrast agents appear opaque due to the difference in absorption of X-rays or other electromagnetic waves and surrounding tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"B6455BDE-CA3E-FB4C-E040-BB89AD437D1D","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"TAYLORT","dateModified":"2020-10-12","changeDescription":"10.12.20 TL changed WFS from RETIRED WITHDRAWN to RETIRED ARCHIVED in preparation of OneData. Use released VM instead.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6455BDE-CA57-FB4C-E040-BB89AD437D1D","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"ONEDATA","dateModified":"2012-01-11","deletedIndicator":"No"},{"value":"Shellfish","valueDescription":"Shellfish","ValueMeaning":{"publicId":"3350343","version":"1","preferredName":"Shellfish","longName":"3350343","preferredDefinition":"Any aquatic invertebrate animal having a shell and belonging to the phylum Mollusca, the class Crustacea (phylum Arthropoda), or the phylum Echinodermata. The term is often used for the edible species of the groups, especially those that are fished or raised commercially.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Shellfish","conceptCode":"C71915","definition":"Any aquatic invertebrate animal having a shell and belonging to the phylum Mollusca, the class Crustacea (phylum Arthropoda), or the phylum Echinodermata. The term is often used for the edible species of the groups, especially those that are fished or raised commercially.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6455BDE-CA63-FB4C-E040-BB89AD437D1D","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6455BDE-CA7C-FB4C-E040-BB89AD437D1D","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"ONEDATA","dateModified":"2012-01-11","deletedIndicator":"No"},{"value":"Seafood","valueDescription":"Seafood","ValueMeaning":{"publicId":"3350344","version":"1","preferredName":"Seafood","longName":"3350344","preferredDefinition":"Seafood","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6455BDE-CA86-FB4C-E040-BB89AD437D1D","latestVersionIndicator":"Yes","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6455BDE-CA9F-FB4C-E040-BB89AD437D1D","beginDate":"2012-01-11","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-01-11","modifiedBy":"ONEDATA","dateModified":"2012-01-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3109741","version":"1","preferredName":"Hypersensitivity Type","preferredDefinition":"An exaggerated response by the immune system to a drug or other substance.:Type; a subdivision of a particular kind of thing.","longName":"C3114 :C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hypersensitivity","conceptCode":"Hypersensitivity","definition":"An exaggerated response by the immune system to a drug or other substance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8903BFCE-CD89-331C-E040-BB89AD431B7C","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"COLLINSP","dateCreated":"2010-06-14","modifiedBy":"ONEDATA","dateModified":"2010-06-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"890261CC-3873-8734-E040-BB89AD435793","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"BIRNBAUA","dateCreated":"2010-06-14","modifiedBy":"SHIDED","dateModified":"2012-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CTEP","type":"USED_BY","context":"CTEP"}],"ReferenceDocuments":[{"name":"Allergies","type":"Preferred Question Text","description":"Allergies","url":null,"context":"NIDCR"},{"name":"CRF Text","type":"Alternate Question Text","description":"Does the participant have allergies to any of the following","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"890261CC-3925-8734-E040-BB89AD435793","latestVersionIndicator":"Yes","beginDate":"2010-06-14","endDate":null,"createdBy":"BIRNBAUA","dateCreated":"2010-06-14","modifiedBy":"SHIDED","dateModified":"2012-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}